Amid reports that Zinbryta (daclizumab) has caused severe and unexpected side effects on the brain, the multiple sclerosis drug has been pulled from the market just two years after it was approved for use.
Zinbryta was originally intended as an alternative to existing multiple sclerosis drug treatment options on the market but quickly lost an audience after early warnings that the drug was associated with severe liver injuries and immune-mediated disorders.
WIth at least three reports of deaths related to the drug and a dozen reports of adverse events, some are wondering whether patients may have a case against the makers of Zinbryta.